16 results about "Mrna level" patented technology

The invention discloses siRNA (small interfering Ribonucleic Acid) of targeted bone morphogenetic protein 2, modified siRNA and application of the siRNA. According to the invention, siRNA drug design is carried out by taking the BMP2 gene as a target gene to obtain a series of siRNAs, siRNAs capable of effectively silencing the mRNA expression level of the BMP2 gene are screened from the siRNAs, and part of siRNA sequences can even silence the mRNA level of the BMP2 gene to about 25%. The siRNA sequence is further modified, wherein phosphorylation or phosphorylation analogue modification, skeleton modification, sugar ring modification and basic group modification are carried out on the 5'terminal of the sequence, or cholesterol molecule modification is carried out on the end group of the siRNA. The siRNA sequence is further subjected to cholesterol modification to obtain a human-mouse homologous sequence of the targeted BMP2 gene, and the in-vivo silencing activity of the BMP2 target spot is further researched in a mouse experimental model subsequently.

This invention belongs to the field of cell detection technology, specifically involving the application of NR4A1 as an early biomarker for gamma-ray radiation. This invention discovers that in the early stage (2 hours) after gamma-ray radiation, the protein and mRNA levels of NR4A1 are significantly increased, exhibiting a radiation dose-dependent effect. NR4A1 can serve as a 2-hour biomarker for gamma-ray irradiated HeLa cells, allowing for the screening of cells irradiated for 2 hours, differentiating the duration of gamma-ray irradiation, and achieving early diagnosis of cellular gamma-ray radiation.

The present application relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of target immune drug for primary liver cancer and application thereof, wherein the combined marker is folate receptor gamma gene FOLR3, stratified protein gene SFN and coiled-coil domain containing 9 gene CCDC9 derived from peripheral blood leukocyte mRNA.The present application performs combined detection based on multiple peripheral blood leukocyte markers, and compared with a single molecular marker, can reduce errors caused by individual expression difference of a single index to some extent, so that the detection result is more accurate.The curative effect prediction model constructed based on detection of peripheral blood leukocyte mRNA level change can specifically recognize and detect in the early stage of tumor formation, has high sensitivity and high specificity, provides an important means for reasonable use of target immune drug for liver cancer patients sensitive or resistant to target immune drug, and has great significance for effective treatment of liver cancer in China.

The present invention relates to a disease-specific biomarker for early prediction and diagnosis of preeclampsia and use thereof, and a composition for prediction or diagnosis of preeclampsia according to an aspect or a method of providing information for prediction or diagnosis thereof, can simply and effectively predict or diagnose the disease by measuring and comparing the mRNA level of a disease-specific protein or a gene encoding the protein changed in a patient.

The present invention relates to a biomarker for diagnosing neuromyelitis optica and its use. Specifically, the present invention relates to a biomarker composition for diagnosing neuromyelitis optica comprising one or more genes selected from the group consisting of Plac8 (placenta-specific 8), Klra2 (killer cell lectin-like receptor, subfamily A, member 2) and Mcoln2 (mucolipin 2) or a protein expressed from said genes; a composition for diagnosing neuromyelitis optica comprising a substance for measuring the mRNA level of said genes or the protein level thereof; a diagnostic kit for neuromyelitis optica comprising said composition; and a method for providing information for predicting and diagnosing neuromyelitis optica.

The application belongs to the technical field of biomarker diagnostic products, and relates to application of UBALD2 as a marker in a hepatocellular carcinoma diagnostic product, and application of a substance for detecting UBALD2 expression level in an in-vitro detection reagent, a detection kit and / or an in-vitro prognosis evaluation product. The application proves that UBALD2 is highly expressed in hepatocellular carcinoma tissues from two aspects of protein level and mRNA level, and indicates that UBALD2 can be used as one of molecular indexes reflecting the occurrence and development state of hepatocellular carcinoma. The application proposes that high expression of UBALD2 is related to poor overall survival of patients, and is related to a later T stage, and indicates that the substance for detecting UBALD2 can be used for prognosis risk evaluation, prognosis stratification and clinical auxiliary judgment products of hepatocellular carcinoma patients, and provides a reference basis for individualized management of patients.

This invention discloses the application of NADK inhibitors in the preparation of drugs for treating liver cancer, such as siRNA targeting NADK. This invention demonstrates that NADK inhibitors can be used to treat liver cancer, and the siRNA provided by this invention exhibits stronger cytotoxicity against HepG2 cells compared to previously disclosed NADK target sequences, effectively inhibiting the proliferation of liver cancer cells both in vitro and in vivo, achieving a tumor-suppressive effect. Furthermore, the siRNA designed in this invention can simultaneously knock down the mRNA levels of both human and mouse NADK genes, facilitating scientific research and the development of tumor drugs.

The application discloses a compound for degrading a target protein in a ubiquitin-proteasome system and a preparation method and application thereof, and a structural general formula of the compound is shown as formula I: R a -linker-SP-linker-R b Formula I; wherein, R a is an E3 ubiquitin ligase ligand; R b is a target protein ligand; SP is a sulfonyl pyridine, a chemical structural formula is shown as formula II; and linker is selected from succinic anhydride, glutaric anhydride, -CO-R 1 -CO- or -NH-R 2 -CO-, wherein, R 1 and R 2 are each independently selected from any substituted C1-C6 alkylene. The compound SD02 for degrading a target protein in the ubiquitin-proteasome system of the application significantly induces polyubiquitination of a STING protein, the SD02 effectively degrades the STING protein through the ubiquitin-proteasome system, in addition, the SD02 shows a dose-dependent reduction of phosphorylation levels of TBK1 and IRF3, can reduce mRNA levels of interferon-related genes induced by SATE-3', 3'-c-di-dAMP, and the SD02 has a cell growth inhibition effect on THP1, U937 and U2OS cells, and the SD02 does not hinder cell proliferation even at a high concentration.

The present invention relates to a composition and method for predicting sulfonylurea dependency in diabetes mellitus patients by identifying the mRNA level of GIPR (gastric inhibitory polypeptide receptor), the level or activity of GIPR protein, or mutations inhibiting the level or activity of GIPR, and for modulating such dependency by regulating these factors.

This invention provides the application of the ApoL1 gene as a diagnostic biomarker for acute myocardial infarction (AMI), belonging to the field of gene function and application. By detecting the expression levels of APOL1 protein and mRNA in peripheral blood of AMI patients and healthy individuals, it was found that the expression level of APOL1 protein in the AMI group was 1.41 times that in the healthy group, and the APOL1 mRNA level in the AMI group was 1.25 times that in the healthy group. Compared with healthy individuals, the mRNA and protein levels of APOL1 in AMI patients were significantly increased, demonstrating that high APOL1 expression is an independent risk factor for AMI and can serve as one of the biomarkers for predicting AMI.

The application discloses a lactobacillus rhamnosus capable of improving oxidative damage to relieve vaginitis, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus has the effect of repairing oxidative damage related symptoms caused by vaginitis, and further improves intestinal health problems caused by vaginitis, specifically embodied in: reducing cell Keap1 mRNA expression, increasing cell supernatant Nrf2 content; improving mouse vaginal oxidative stress: activating the Keap1 / Nrf2 pathway, increasing the Nrf2 level of vaginal tissue; enhancing the antioxidant capacity of the mouse intestinal tract: reducing the Keap1 mRNA level of colon tissue; improving the pathological characteristics of the mouse vagina and reducing the pathogenic bacterial load. Therefore, the lactobacillus rhamnosus CCFM1315 has great application prospect in products for improving and repairing the vaginal oxidative damage problems caused by vaginitis.

The application relates to a kit for detecting the differentiation state of fruit fly testis spermatogonia and an application thereof, wherein the kit comprises reagents for detecting the expression level of a Bckdhb gene, the Bckdhb gene being a dominant expression gene in fruit fly testis tissue. By using a UAS / Gal4 system to specifically knock down Bckdhb in spermatogonia and driving the Bckdhb by Bam-Gal4, it is found that the down-regulation of the Bckdhb expression level can cause the spermatogonia differentiation to be blocked, the testis top nucleus deepening distance is increased, the germ cell differentiation is defective, meanwhile, the Bckdhb mRNA level is significantly decreased, and the Piwi mRNA level is significantly increased. The expression level of the Bckdhb can be detected to effectively judge the differentiation state of the spermatogonia. The kit provided by the application can be used for fruit fly testis spermatogonia differentiation research, and has important scientific research application value.

The present disclosure relates to the use of mesenchymal stem cells in the preparation of a drug for treating fibrotic diseases and a pharmaceutical composition. The mesenchymal stem cells are mesenchymal stem cells with knocked down TGFβ1 expression. The pharmaceutical composition contains mesenchymal stem cells with knocked down TGFβ1 expression. The mesenchymal stem cells with knocked down TGFβ1 expression can reduce the content of hydroxyproline in lung tissue and the lung weight index, and improve the lung function improvement rate; can also reduce the content of hydroxyproline in liver tissue, the mRNA level of α-SMA and Col I (α1), and the area proportion of liver fibrosis; has a good effect on treating fibrotic diseases, and the curative effect is stable.

The application discloses application of a rice OsRING83 gene in improving rice blast resistance, and belongs to the field of genetic engineering. The application constructs transgenic rice by overexpressing the OsRING83 gene in the rice, and finds that overexpression of the OsRING83 gene significantly improves the resistance of the rice to the blast fungus through disease resistance detection. Therefore, the OsRING83 gene can be introduced into the rice as a target gene to improve the disease resistance of the rice and improve the rice variety. The application also proves that the protein expressed by the introduced OsRING83 gene effectively improves the defense ability of the rice by promoting the mRNA level of a defense-related gene OsPR10, and has important significance for rice improvement and breeding.

This invention discloses an in vitro detection method and kit for assisting in the screening of systemic lupus erythematosus (SLE) patients suitable for BCMA-CD19 dual-target CAR-T therapy. Based on single-cell transcriptome sequencing, this invention identifies a plasma cell subset that exhibits high XBP1 / JCHAIN ​​expression but low CD19 expression after CD19 single-target therapy. This method uses qPCR to quantitatively detect the mRNA levels of AIM2, XBP1, JCHAIN, and immunoglobulin heavy chain constant region genes in PBMCs, and calculates the BCR category switching score using an exponential operational model. Patients exhibiting high expression of AIM2 or plasma cell markers and a BCR score >1.5 (indicating IgG / IgA dominance) are considered suitable for dual-target therapy. This method effectively identifies individuals at risk of single-target therapy escape and can be used to assess the quality of immune reconstitution after treatment.

The application discloses an application of inducing sputum CC16 as a prediction marker of COPD severity and eosinophil subtype. The application finds that the expression of CC16 in induced sputum of mild and moderate COPD patients and severe and very severe COPD patients has significant difference by detecting and analyzing various inflammatory molecules in induced sputum, and can distinguish eosinophilic COPD. The application establishes a regression model based on FEV1pred% and the relative expression level of CC16 mRNA, and the model has good sensitivity, specificity and accuracy. Therefore, the mRNA level of induced sputum CC16 has good application prospect for evaluating the severity of COPD and diagnosing the eosinophil subtype. The application can evaluate the severity of COPD and diagnose the eosinophil subtype in a more simple way, and based on the characteristics of the biomarker, a more reliable non-invasive kit can be prepared.